Related Experiment Videos

Changes in serum KL-6 after intravenous fosfomycin administration in idiopathic interstitial pneumonia

Niro Okimoto1, Takeyuki Kurihara, Kohichi Osaki

  • 1Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School Kawasaki Hospital, Okayama, Japan. kh-info@po.rweb.ne.jp

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
|March 3, 2004
PubMed

Insights

Intravenous fosfomycin (FOM) significantly reduced serum KL-6 levels in patients with idiopathic interstitial pneumonia (IIP). This suggests FOM may be a beneficial therapeutic option for IIP, improving a key biomarker.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Biochemistry

Background:

  • Idiopathic interstitial pneumonia (IIP) is a group of lung diseases characterized by progressive scarring.
  • Serum KL-6 is a biomarker often elevated in IIP, reflecting lung injury and fibrosis.
  • Effective therapeutic options for IIP remain limited, necessitating further research into novel treatments.

Purpose of the Study:

  • To investigate the effect of intravenous fosfomycin (FOM) on serum KL-6 levels in patients with IIP.
  • To evaluate the potential of FOM as a therapeutic agent for IIP by monitoring changes in a key disease biomarker.

Main Methods:

  • Seventeen patients diagnosed with usual interstitial pneumonia (UIP) via surgical lung biopsy were enrolled.
  • FOM was administered intravenously at a dose of 2 grams twice daily for 14 days.
  • Serum KL-6 levels were measured before and after the 14-day treatment period.

Main Results:

  • A statistically significant reduction in serum KL-6 levels was observed in all 17 patients following FOM administration (from 1273 +/- 132 U/ml to 1023 +/- 101 U/ml; P < 0.01).
  • The decrease in serum KL-6 suggests a potential anti-fibrotic or anti-inflammatory effect of FOM in this patient cohort.

Conclusions:

  • Intravenous fosfomycin administration led to a significant decrease in serum KL-6 levels in patients with idiopathic interstitial pneumonia.
  • FOM demonstrates potential as an appropriate therapeutic drug for IIP, warranting further clinical investigation.

Related Concept Videos

Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...